Dalbavancin and Telavancin in the treatment of infective endocarditis: a literature review.

Dalbavancin and Telavancin in the treatment of infective endocarditis: a literature review.

Int J Antimicrob Agents. 2020 Jul 03;:106072

Authors: Lampejo T

Abstract
Glycopeptides have an established role in the management of infective endocarditis and feature in current treatment guidelines. Newer lipoglycopeptide agents (dalbavancin, telavancin and oritavancin), which are analogues of glycopeptides with structural modifications giving rise to added novel mechanisms of antimicrobial activity, are approved for the treatment of gram-positive skin and skin structure infections and also for nosocomial pneumonia (only telavancin has approval for the latter indication). Recent evidence has also emerged to support their use in the treatment of bone and joint infections. This article reviews the current literature on dalbavancin and telavancin in the treatment of infective endocarditis, a condition for which the role of these agents is yet to be established.

PMID: 32629114 [PubMed - as supplied by publisher]